Donor T cells depleted of CD62L+ cells (University College, London)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameDonor T cells depleted of CD62L+ cells (University College, London)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionLeukocyte adhesion molecule-1 inhibitorsT lymphocyte replacements
TargetsLeukocyte adhesion molecule-1
Therapy Area/IndicationsGraft vs Host DiseasePrimary Immunodeficiency DiseasesMyelodysplastic Syndromes +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity College London
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseasePrimary Immunodeficiency DiseasesMyelodysplastic Syndromes +[7] 

Other Information

ATC CodeN/A
Related LinksN/A